A 37 year-old woman with late-stage refractory diffuse large B cell lymphoma…

Cancer History:

First diagnosis of cancer: 05/2011 non- Hodgkin’s lymphoma (NHL), diffused large B- cell lymphoma(DLBCL)

First recurrence date: 03/2013 sites: multiple lymph nodes

Refractory or persistent disease sites: multiple lymph nodes were involved in the upper and  lower parts of the diaphragm, the abdominal cavity lymph nodes compressed on the ureter and led to the right kidney atrophy

Therapy gone through: Surgery: no

Chemotherapy: 8 courses of R-CHOP, 4 courses of rituximab, 8 courses of GA101 clinical trials, 3 courses of DICE, 1 course of high dose MTX (1g), 2 courses of GEMOX, 2 courses of E-POCH, and 1 course of ESHAP;

Radiotherapy: no Targeted drugs: no Immunotherapy: no others: no

Clinical Trial Number: NCT03050190 ; enrolled date: 08/01/2015

Interventions: 4SCART (targeting CD19), IV after lymphodepletion with Flu-Cy

CRS Grade: 1; other side effects: fevers

Treatment response: CR Quality of Life: return to normal life

Progression-free interval: 4 years 8 months

Current status: No evidence of disease

Disease images before and after CART (with time)

References:

1）Chang LJ, Dong LJ, Zhu J. et al. (2015) 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. Blood 126 (23), 264.

2）Jing HM, Chang LJ, Chen MY, Bao F, Wang J, Wang WM, Liu YY, Kuo HH, Liu YC, Dong LJ. (2015) Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy. Blood 126 (23), 5130.

3）L-J Chang, Lujia D, Liu Y-C, Tsao S-T, Li Y-C, Liu L, Gao Z, Tan X, Lu D-P, Zhang J-P, Wang J-B, Ying Y-M, Zhang L-P, Zheng H, Wang K, Zheng X-L, Wang H-X, Lai X, and Li D (2016) Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study. Blood 128 (22), 587.

4） Hao L, Li T, Chang L-J and Chen X. (2017) Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T cells: a systematic review of efficacy and safety. Curr Med Chem.

5）Chang, L.-J., Li, Y. Tu, S. et al. Phase I/II Trial of Multi-Target Chimeric Antigen  Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas. (2018) Blood 132:225.